Cite
HARVARD Citation
Kasahara, K. et al. (n.d.). 3072 Phase 2: Docetaxel with or without ramucirumab as therapy for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations after prior EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy. European journal of cancer. pp. S620-. [Online].